Trial Profile
An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Enfortumab vedotin (Primary) ; Docetaxel; Paclitaxel; Vinflunine
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms EV-301
- Sponsors Astellas Pharma Global Development
- 08 Jan 2024 Planned End Date changed from 29 Feb 2024 to 31 Aug 2024.
- 05 Sep 2023 Results exploratory analysis evaluating efficacy and safety data for enfortumab vedotin versus chemotherapy over median follow-up of approximately 2 years, published in the Annals of Oncology
- 21 Apr 2023 This trial has been completed in Belgium, according to the European Clinical Trials Database record.